Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Cobalt confirms June market debut

(Sharecast News) - Cobalt Holdings confirmed on Monday it would be joining the London Stock Exchange next month in a $230m initial public offering. The firm said it expected to start trading on the main market on or around 10 June, with Anglo-Swiss commodity trader Glencore and investment firm Anchorage participating as cornerstone investors.

Glencore will invest $24.3m, giving it a stake of around 10% post-IPO, while Anchorage will own around 9.5% following a $23m investment.

The UK firm, which purchases and holds the metal, was created to give investors direct exposure to the price of cobalt.

Used in make high-performance batteries found in electric cars, portable electronics and energy storage systems, demand for cobalt more than doubled between 2015 and 2024.

Oversupply, however, has weighed heavily on prices recently, and it is now trading at around $11 per pound, compared to just below $44 per pound in 2022.

However, announcing the IPO at the start of May, Cobalt Holdings argued the weaker prices was an opportunity to stockpile the metal. The green energy transition is expected to support ongoing strong demand, it argued, while the Democratic Republic of Congo - the world's largest producer of the metal - has started to introduce export restrictions.

Cobalt Holdings has a six-year contract with Glencore, which will see the trader sell it cobalt worth up to $1bn, while its agreement with Anchorage could see it acquire up to 1,500 tonnes in 2031.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.